Alisporivir clinical trials
Also written DEB025 and Debio 025.
How each study uses alisporivir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 1
Debiopharm International SA (12) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses alisporivir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)CompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT04608214Written as AlisporivirHow we know
- Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1TerminatedPhase 3Debiopharm International SANCT01446250Written as AlisporivirHow we know
- Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionCompletedPhase 2Debiopharm International SANCT02094443Written as AlisporivirHow we know
- Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve ParticipantsCompletedPhase 3Debiopharm International SANCT01318694Written as AlisporivirHow we know
- Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve ParticipantsCompletedPhase 2Debiopharm International SANCT01215643Written as AlisporivirHow we know
- Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C PatientsCompletedPhase 3Debiopharm International SANCT02753699Written as AlisporivirHow we know
- Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous TreatmentCompletedPhase 2Debiopharm International SANCT01183169Written as AlisporivirHow we know
- Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy SubjectsCompletedPhase 1Debiopharm International SANCT01975337Written as AlisporivirHow we know
- Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CTerminatedPhase 3Debiopharm International SANCT01500772Written as AlisporivirHow we know
- Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedPhase 1Debiopharm International SANCT01860326Written as AlisporivirHow we know
- Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsCompletedNot applicableDebiopharm International SANCT01970904Written as AlisporivirHow we know
- A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsCompletedNot applicableDebiopharm International SANCT00854802Written as Debio 025How we know
- A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard TreatmentCompletedPhase 2Debiopharm International SANCT00537407Written as Debio 025How we know
Given beside what is tested · 1 — alisporivir is usual care or a partner of the new treatment
Codes
What other systems call alisporivir · ClinicalTrials.gg INT004762
- MeSH (NLM) C499715alisporivirOne source NLM
- UNII (FDA) VBP9099AA6ALISPORIVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q4727236alisporivirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169774AlisporivirOne source FDA
- DrugBank DB12139One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C499715 | alisporivir | One source NLM |
| UNII (FDA) | VBP9099AA6 | ALISPORIVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4727236 | alisporivir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169774 | Alisporivir | One source FDA |
| DrugBank | DB12139 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.